Clinical Trial Update: A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

View source ↗

Summary

A clinical trial evaluating evolocumab (Repatha) plus standard of care versus standard of care alone on major cardiovascular events in Chinese participants with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Repatha (Evolocumab)

Snippet

Sponsor: Amgen | Conditions: Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease | Status: RECRUITING